Xilio Therapeutics, Inc.XLONASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank74
3Y CAGR-5.7%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-5.7%/yr
Quarterly compound
Percentile
P74
Within normal range
vs 3Y Ago
0.8x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 11.73% |
| Q3 2025 | -11.04% |
| Q2 2025 | -16.38% |
| Q1 2025 | 30.66% |
| Q4 2024 | 3.33% |
| Q3 2024 | 8.46% |
| Q2 2024 | -5.28% |
| Q1 2024 | 3.26% |
| Q4 2023 | -5.78% |
| Q3 2023 | -1.50% |
| Q2 2023 | -13.37% |
| Q1 2023 | -9.49% |
| Q4 2022 | 13.98% |
| Q3 2022 | -13.70% |
| Q2 2022 | 31.76% |
| Q1 2022 | -23.16% |
| Q4 2021 | 49.41% |
| Q3 2021 | 4.35% |
| Q2 2021 | 7.41% |
| Q1 2021 | 67.32% |
| Q4 2020 | -7.43% |
| Q3 2020 | 37.52% |
| Q2 2020 | 7.93% |
| Q1 2020 | 0.00% |